Annabelle L. Fonseca

Annabelle L. Fonseca

Auto-generated profile, based on publicly available information

Annabelle L. Fonseca

Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama; Division of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AFAnnabelle L. Fonseca
Annabelle L. Fonseca
HKHamza Khan
Hamza Khan
KMKrista R. Mehari
Krista R. Mehari
DCDeepa Cherla
Deepa Cherla
MHMartin J. Heslin
Martin J. Heslin
FJFabian M. Johnston
Fabian M. Johnston

27 August 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AFAnnabelle L. Fonseca
Annabelle L. Fonseca
DCDeepa Cherla
Deepa Cherla
AKAnai N. Kothari
Anai N. Kothari
CTChing-Wei D. Tzeng
Ching-Wei D. Tzeng
MHMartin J. Heslin
Martin J. Heslin
HTHop S. Tran-Cao
Hop S. Tran-Cao

11 October 2022 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
HKHamza Khan
Hamza Khan
MHMartin J. Heslin
Martin J. Heslin
ECErrol D. Crook
Errol D. Crook
KMKrista Mehari
Krista Mehari
FJFabian M. Johnston
Fabian M. Johnston
AFAnnabelle L. Fonseca
Annabelle L. Fonseca

8 August 2023 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
KAKrisha Amin
Krisha Amin
HKHamza Khan
Hamza Khan
LHLarry R. Hearld
Larry R. Hearld
DCDaniel I. Chu
Daniel I. Chu
VPVictoria Prete
Victoria Prete
AFAnnabelle L. Fonseca
Annabelle L. Fonseca

28 September 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HKHamza Khan
Hamza Khan
DCDeepa Cherla
Deepa Cherla
KMKrista Mehari
Krista Mehari
MTManish Tripathi
Manish Tripathi
TBThomas W. Butler
Thomas W. Butler
AFAnnabelle L. Fonseca
Annabelle L. Fonseca

15 March 2024 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
AFAnnabelle L Md Fonseca
Annabelle L Md Fonseca
RARida Ahmad
Rida Ahmad
KAKrisha Bs Amin
Krisha Bs Amin
MTManish Be Tripathi
Manish Be Tripathi
VVVijay Vobbilisetty
Vijay Vobbilisetty
MHMartin J Md Heslin
Martin J Md Heslin
BACKGROUND: Receipt of guideline-concordant treatment (GCT) is associated with improved prognosis in foregut cancers. Studies show that patients living in areas of high neighborhood deprivation have worse healthcare outcomes; however, its effect on GCT in foregut cancers has not been evaluated. We studied the impact of the area deprivation index (ADI) as a barrier to GCT. STUDY DESIGN: A single-institution retrospective review of 498 foregut cancer patients (gastric, pancreatic, and hepatobiliary adenocarcinoma) from 2018 to 2022 was performed. GCT was defined based on National Comprehensive Cancer Network guidelines. ADI, a validated measure of neighborhood disadvantage was divided into terciles (low, medium, and high) with high ADI indicating the most disadvantage. RESULTS: Of 498 patients, 328 (66%) received GCT: 66%, 72%, and 59% in pancreatic, gastric, and hepatobiliary cancers, respectively. Median (interquartile range) time from symptoms to workup was 6 (3 to 13) weeks, from diagnosis to oncology appointment was 4 (1 to 10) weeks, and from oncology appointment to treatment was 4 (2 to 10) weeks. Forty-six percent were diagnosed in the emergency department. On multivariable analyses, age 75 years or older (odds ratio [OR] 0.39 [95% CI 0.18 to 0.87]), Black race (OR 0.52 [95% CI 0.31 to 0.86]), high ADI (OR 0.25 (95% CI 0.14 to 0.48]), 6 weeks or more from symptoms to workup (OR 0.44 [95% CI 0.27 to 0.73]), 4 weeks or more from diagnosis to oncology appointment (OR 0.76 [95% CI 0.46 to 0.93]), and 4 weeks or more from oncology appointment to treatment (OR 0.63 [95% CI 0.36 to 0.98]) were independently associated with nonreceipt of GCT. CONCLUSIONS: Residence in an area of high deprivation predicts nonreceipt of GCT. This is due to multiple individual- and system-level barriers. Identifying these barriers and developing effective interventions, including community outreach and collaboration, leveraging telehealth, and increasing oncologic expertise in underserved areas, may improve access to GCT.